Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFRm Advanced Non-Small Cell Lung Cancer”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Early research (Phase 1)Looking for participantsNCT06147037
What this trial is testing

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Who this might be right for
Advanced Solid TumorMetastatic Colorectal CarcinomaHead and Neck Squamous Cell Carcinoma+4 more
AstraZeneca 70
Not applicableApproved For MarketingNCT06279728
What this trial is testing

Medical Access Program for Datopotamab Deruxtecan in EGFRm NSCLC Patients

Who this might be right for
EGFRm Advanced Non-Small Cell Lung CancerEGFRm Metastatic Non-Small Cell Lung Cancer
Daiichi Sankyo
Testing effectiveness (Phase 2)Active Not RecruitingNCT05801029
What this trial is testing

Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca 60
Testing effectiveness (Phase 2)Ended earlyNCT02630186
What this trial is testing

A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Clovis Oncology, Inc. 3
Testing effectiveness (Phase 2)UnknownNCT06195189
What this trial is testing

Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II

Who this might be right for
Non Small Cell Lung Cancer
Sichuan University 40
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Not applicableUnknownNCT02988141
What this trial is testing

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

Who this might be right for
Nonsmall Cell Lung Cancer
Jianxing He 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06319950
What this trial is testing

High-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall Cell
Taizhou Hospital 255
Not applicableStudy completedNCT06039683
What this trial is testing

A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region

Who this might be right for
Carcinoma, Non-Small-Cell Lung
AstraZeneca 54
Testing effectiveness (Phase 2)Ended earlyNCT05215951
What this trial is testing

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC

Who this might be right for
Lung Cancer
AstraZeneca 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Not applicableStudy completedNCT04031898
What this trial is testing

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

Who this might be right for
Lung Cancer
AstraZeneca 896
Large-scale testing (Phase 3)Active Not RecruitingNCT04765059
What this trial is testing

Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca 98
Testing effectiveness (Phase 2)Ended earlyNCT02495233
What this trial is testing

ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Who this might be right for
Non-Small-Cell Lung Cancer
Astellas Pharma Global Development, Inc. 10
Early research (Phase 1)Study completedNCT02908750
What this trial is testing

Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 24
Testing effectiveness (Phase 2)Study completedNCT04770688
What this trial is testing

Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR MutationLocally Advanced Solid TumorMetastatic Cancer+1 more
Shanghai Chest Hospital 25
Early research (Phase 1)Not Yet RecruitingNCT06218940
What this trial is testing

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

Who this might be right for
NSCLC Stage IV
Newsoara Biopharma Co., Ltd. 40
Large-scale testing (Phase 3)Study completedNCT02296125
What this trial is testing

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
AstraZeneca 674
Testing effectiveness (Phase 2)Looking for participantsNCT06574347
What this trial is testing

Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.

Who this might be right for
Non-Small-Cell Lung Cancer
Avistone Biotechnology Co., Ltd. 120
Load More Results